Jul 16, 2025 · The treatment of metastatic hormone-sensitive prostate cancer has evolved rapidly, with the emergence of doublet and triplet therapies transforming outcomes. However, these advances …

The treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has changed radically in recent years. Androgen deprivation therapy (ADT) alone was for decades the standard of …

Apr 1, 2025 · This narrative collaborative review summarises the data behind combination treatment approaches for locally advanced prostate cancer (LAPC) and mHSPC, and discusses on-going …

Feb 10, 2026 · Traditionally, treatment of mCSPC was androgen deprivation therapy (ADT) until progression to castration-resistant prostate cancer (CRPC), at which stage alternative treatments …

Mar 20, 2023 · Annually, >1.2 million new cases of prostate cancer are diagnosed and global prostate cancer-related deaths exceed 350 000 per annum, making it one of the leading causes of cancer …

Mar 26, 2026 · Christopher Sweeney discusses treatment evolution in metastatic hormone-sensitive prostate cancer, where 8-year overall survival has climbed to approximately 50% with ADT plus an …

Apr 8, 2026 · Looking ahead, I am very optimistic about the future of prostate cancer treatment. The field is clearly moving toward more precise and individualized care, particularly in metastatic …

Treatment of metastatic prostate cancer is generally based on whether its growth can be slowed or stopped with hormone therapy. Recall that testosterone (an androgen hormone) is the “fuel” that …

Apr 9, 2026 · A potential shift in the management of metastatic hormone-sensitive prostate cancer (mHSPC) has emerged following the release of topline results from Pfizer’s Phase 3 TALAPRO-3 …

SUMMARY Purpose The management of advanced prostate cancer is rapidly evolving. To assist in clinical decision-making, evidence-based guideline statements were developed to provide a rational …